Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth

Massa, Katherine; Childress, Katherine Scolari; Vricella, Laura K.; Boerrigter, Ashley; Franklin, Briana H.K.; Sauer, Megan; Armbruster, Raina; Tomlinson, Tracy M.

doi:10.1016/j.ajogmf.2020.100219

Cited by 5 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One observational study had already reported rPTB to be slightly more frequent in largely Hispanic cohort of 430 women treated with 17-OHPC than in comparable patients who had received care before 17-OHPC treatment was introduced [ 13 ]. A more recent retrospective cohort study of over 800 predominantly black and high risk white women found that treatment with 17-OHPC was not associated with prolongation of pregnancy to 35 weeks’ gestation or later [ 14 ]. Thus, we report here the third relatively large observational study to contradict findings of the Meis trial, and the second of these conducted in a largely Hispanic population.…”

Section: Discussionmentioning

confidence: 99%

Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study

Mazza,

Komatsu,

Ponzio

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background Preterm birth is a leading cause of infant morbidity and mortality worldwide. The burden of prematurity underscores the need for effective risk reduction strategies. The purpose of this study is to evaluate the efficacy of progesterone therapy, both intramuscular 17-α-hydroxyprogesterone caproate (IM 17-OHPC) and vaginal progesterone, in the prevention of recurrent spontaneous preterm birth (sPTB). The co-primary outcomes included: recurrent spontaneous PTB < 37 and < 34 weeks’ gestation. Methods This retrospective cohort study included 637 pregnant patients that delivered at any of the three hospitals within the Los Angeles County healthcare system between October 2015 and June 2021. We compared frequencies of measured variables between each of the progesterone treated groups to no treatment using Pearson chi-squared tests and independent t-tests for categorical and continuous variables, respectively. We estimated crude and adjusted associations between each specific treatment (versus no treatment) and primary outcomes using logistic regression. Results Recurrent sPTB < 37 weeks’ gestation occurred in 22.3% (n = 64) of those in the no treatment group, 29.1% (n = 86, p = .077) in the 17-OHPC group, and 14.3% (n = 6, p = 0.325) in the vaginal progesterone group. Recurrent sPTB < 34 weeks’ gestation was 6.6% (n = 19) in the no treatment group, 11.8% (n = 35, p = .043) in the 17-OHPC group, and 7.1% (n = 3, p = 1) in the vaginal progesterone group. Among all participants, neither 17-OHPC nor vaginal progesterone was significantly associated with a reduction in recurrent sPTB at any time point. Among those with a short cervix, IM 17-OHPC was positively associated with recurrent sPTB < 37 weeks’ gestation (aOR 5.61; 95% CI 1.16, 42.9). Conclusions Progesterone therapy of any type did not reduce the risk of recurrent sPTB < 34 or < 37 weeks’ gestation compared to no progesterone therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study

Mazza,

Komatsu,

Ponzio

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

show abstract

“…Pregnancy duration with use of 17-αhydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth (Massa et al, 2020).…”

Section: Título Del Artículo Limitacionesmentioning

confidence: 99%

Uso de Progesterona y Caproato 17-Alfa-Hidroxiprogesterona como Reducción del Riesgo de Parto Pretérmino: Revisión Sistemática

Nuñez Daza,

Madariaga Leon,

Vega Acevedo

2024

Ciencia Latina

View full text Add to dashboard Cite

Introducción El parto prematuro es una de las principales causas de morbilidad y mortalidad infantil a nivel mundial. Se define como parto prematuro todo parto antes de las 37 semanas. Uno de los mecanismos de la enfermedad es la disminución prematura de la acción de la progesterona. Objetivo: Comparar la asociación entre el uso de progesterona y caproato de 17- alfa- hidroxiprogesterona (17-OHPC) en la prevención del parto pretérmino. Métodos: Se realizó una revisión bibliográfica haciendo uso de palabras clave incluidas en los términos Descriptores en Ciencias de la Salud (DesC) / Medicas Subject headings (MeHS), publicados en las bases de datos de Pubmed, Scopus, Uptodate y Scielo entre el período del año 2015 hasta la actualidad, en español e inglés. Resultados: La progesterona vaginal y natural micronizada (PNM) es una mejor alternativa que la 17-OHPC para la prevención de síndrome de parto pretérmino antes de la semana 34, en gestaciones de feto único. Conclusiones: La progesterona vaginal presentó mejores resultados en la prevención de parto pretérmino y prolongación de semanas de embarazo en embarazos únicos comparado con la PNM y 17-OHPC. Los estudios analizados pueden tener sesgos, la decisión del uso se deja a criterio clínico de cada profesional.

show abstract

Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis

Conde-Agudelo

Romero

2022

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth

Cited by 5 publications

References 27 publications

Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study

Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study

Uso de Progesterona y Caproato 17-Alfa-Hidroxiprogesterona como Reducción del Riesgo de Parto Pretérmino: Revisión Sistemática

Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis

Contact Info

Product

Resources

About